According to the first author of the study George Thomas, “It’s really promising to see measures like this, which can potentially track the varying progression of Parkinson’s disease, as it could help clinicians devise better treatment plans for people based on how their condition manifests.”

The co-author of the study, Dr. Julio Acosta-Cabronero from Tenoke Ltd. and the Wellcome Centre for Human Neuroimaging, UCL, also comments on the findings: